Streetbeat News

Products Services

VKTX

Viking Therapeutics shares surged following the announcement of positive results from its Phase 1 multiple ascending dose clinical trial of VK2735, an oral tablet formulation.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:45 am

BYDDF

NIO

China has filed a WTO complaint against the U.S. over its EV tax credit program, claiming it discriminates against foreign manufacturers by requiring EVs to be assembled in North America with domestically sourced batteries. The Inflation Reduction Act's provisions are said to distort competition and disrupt the global NEV supply chain. Chinese EV maker BYD, now leading in global sales, and Nio Inc. express concerns over market access and treatment compared to U.S. companies.

Portfolio Pulse from Benzinga Neuro

March 26, 2024 | 11:36 am

VRCA

Verrica Pharmaceuticals' lead product, YCANTH, has been granted New Chemical Entity (NCE) status and listed in the FDA's Orange Book, ensuring at least five years of regulatory exclusivity. The company's U.S. patents for YCANTH are expected to expire between 2034 and 2041, potentially extending exclusivity further.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:33 am

BTGOF

BUG

SPRX

ZS

Zscaler, Inc. (NASDAQ:ZS) has expanded its partnership with U.K.-based BT Group Plc (OTC:BTGOF) to enhance cloud security offerings through the Zscaler AI-driven Zero Trust Exchange platform. This collaboration will also provide BT Group with security solutions for its operations, aiming to improve business agility, efficiency, resilience, and security for BT's customers. Zscaler's financial outlook includes a Q3 non-GAAP income from operations forecast of $98 million to $100 million and a net income per share of 64 to 65 cents. For fiscal year 2024, the forecast is $395 million to $400 million for non-GAAP income from operations and $2.73 to $2.77 for net income per share. ZS stock has seen over a 73% increase in the past year and is trading higher by 0.50% to $195.05 in the premarket session.

Portfolio Pulse from Nabaparna Bhattacharya

March 26, 2024 | 11:16 am

NSPR

InspireMD announced that an abstract of one-year follow-up results from its C-GUARDIANS U.S. Investigational Device Exemption clinical trial has been accepted for presentation at LINC 2024. This development could indicate positive progress in their clinical trials and potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:14 am

NOVA

Sunnova Energy International Inc. (NOVA) has been announced as the exclusive provider of solar and battery storage services in Home Depot stores throughout the United States and its territories. This partnership aims to expand the accessibility and adoption of renewable energy solutions among consumers.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:11 am

MRNA

Moderna has announced that its MRNA-1283 vaccine met the primary endpoints in a Phase 3 clinical trial, indicating positive results.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:03 am

STOK

Stoke Therapeutics' stock price increased following the announcement of positive Phase 1/2a data for STK-001, indicating its potential effectiveness in treating Dravet syndrome.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 10:58 am

PRAX

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced successful Phase 2a study results for PRAX-628, showing a 100% response rate in treating epilepsy patients with Photo Paroxysmal Response (PPR). The study's positive outcome highlights PRAX-628's potential as an effective anti-seizure medication.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 10:32 am

BEAM

Beam Therapeutics Inc. announced the UK Medicines and Healthcare Products Regulatory Agency has cleared its clinical trial authorization for BEAM-302, aimed at treating alpha-1 antitrypsin deficiency (AATD).

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 10:31 am